US Oncology Market to Reach $212 Billion by 2034, Driven by Precision Therapies.
ByAinvest
Wednesday, Dec 24, 2025 6:05 am ET1min read
CRBU--
GTBP--
LYEL--
NRIX--
SLS--
The US oncology market is expected to grow from $81 billion in 2025 to $212 billion by 2034, driven by a shift towards targeted therapies and immunotherapies that offer precision mechanisms for combating resistant cancer forms. Companies such as GT Biopharma, Lyell Immunopharma, Caribou Biosciences, SELLAS Life Sciences, and Nurix Therapeutics are poised to benefit from this trend, with the pancreatic cancer precision medicine market predicted to surge from $823 million in 2025 to $4.03 billion by 2034.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet